Mucormicosis invasora en pacientes con COVID-19: reporte de 2 casos

• Autores: Dana Camhi, María Ignacia López, Alan Wiener, Karin Heinriksen, Ignacio Pérez, Fernando Verdugo, Reinaldo Rosas, Pamela Farías
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 151, Nº. 1, 2023, págs. 125-128
• Idioma: español
• Títulos paralelos:
  • Invasive mucormycosis during COVID-19 infection. Report of two cases
• Enlaces
  • Texto completo
• Resumen

  • COVID-19 disease is associated with a significant number of opportunistic infections, including invasive fungal infections such as mucormycosis. The prevalence of the latter is rare, estimated to be between 0.005 and 1.7 per million inhabitants. Risk factors include hematological diseases, Diabetes Mellitus with poor metabolic control, solid organ transplantation, neutropenia, and prolonged administration of systemic corticosteroids. We report two males aged 60 and 75 years with pulmonary and tracheobronchial invasive mucormycosis, respectively. Both patients had a deficient metabolic control of their diabetes as a predisposing risk factor added to severe COVID-19 infection. High suspicion and early diagnosis are essential for prompt treatment, especially considering the associated high morbidity and mortality of this fungal infection.